Pompe Disease Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

PRESS RELEASE
Published March 16, 2023

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 20+ pipeline drugs in the Pompe Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Pompe Disease therapeutics market is anticipated to evolve immensely in the coming years owing to the improvement in the diagnosis methodologies, rising disease awareness, incremental healthcare spending worldwide, and the estimated launch of emerging therapies.

Pompe Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Pompe Disease Market.

The Pompe Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Pompe Disease Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Pompe Disease and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pompe Disease Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Pompe Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Companies across the globe are diligently working toward the development of novel treatment therapies, with a considerable amount of success over the years. Key players, such as Sanofi, Actus, Amicus, Roche, and others, are developing therapies that will enhance treatment outcomes in Pompe patients.

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates

Route of Administration
Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

– Intranasal
– Intrathecal
– Intravenous
– Oral
– Oral/Intravenous
– Parenteral
– Subcutaneous
– Subcutaneous/Intramuscular
– Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as

– Antisense oligonucleotide
– Gene therapy
– Hormones
– Neuropeptides
– Oligonucleotides
– Small Molecule
– Triglyceride

Mechanism of Action of the Emerging Pipeline Therapies

– Alpha glucosidase replacement
– Glycogen synthase inhibitor
– RNA interference
– Alpha glucosidase expression stimulant

Pompe Disease Therapeutics Landscape

There are approx. 15+ key companies developing therapies for Pompe Disease. Currently, Amicus Therapeutics is leading the therapeutics market with its Pompe Disease drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Pompe Disease Therapeutics Market include:

– Asklepios Biopharmaceutical
– Astellas Pharma Inc
– BioMarin Pharmaceutical
– Amicus Therapeutics
– Spark Therapeutics
– Maze Therapeutics
– Denali Therapeutics
– Rocket Pharmaceuticals
– Audentes Therapeutics
And Many Others

Pompe Disease Emerging and Market Drugs Covered in the Report Include:

– AT-GAA: Amicus Therapeutics
– SPK-3006: Spark Therapeutics
– MZE 001: Maze Therapeutics
– SPK-3006: Spark Therapeutics
– M 021: M6P Therapeutics
– AAV2/8LSPhGAA: Asklepios Biopharmaceutical
– SPK-3006: Spark Therapeutics
– Cipaglucosidase alfa: Amicus Therapeutics
And Many more

Explore More About the Emerging Drugs and Key Companies: Pompe Disease Pipeline Development Activities

Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Pompe Disease Current Treatment Patterns
4. Pompe Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Pompe Disease Late-Stage Products (Phase-III)
7. Pompe Disease Mid-Stage Products (Phase-II)
8. Pompe Disease Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pompe Disease Discontinued Products
13. Pompe Disease Product Profiles
14. Key Companies in the Pompe Disease Market
15. Key Products in the Pompe Disease Therapeutics Segment
16. Dormant and Discontinued Products
17. Pompe Disease Unmet Needs
18. Pompe Disease Future Perspectives
19. Pompe Disease Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Pompe Disease Therapeutic Outlook

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Newsmantraa